Vertex Pharmaceuticals Incorporated (VX1.DE) Stock Analysis & Winston Score

Vertex Pharmaceuticals is a biotech company that makes medicines for serious genetic diseases. Its main products are pills that treat cystic fibrosis, a rare lung disease affecting roughly 160,000 people worldwide. Vertex dominates this market — its drug combination Trikafta is used by the vast majority of eligible cystic fibrosis patients in the United States and Europe. Vertex makes money by selling prescription drugs directly to patients through insurers and healthcare systems. It operates primarily in the US and Europe, generating over $9 billion in annual revenue. Its grip on the cystic fibrosis market is strong because developing these medicines took decades of research and competitors have struggled to match its results. The key risk is that cystic fibrosis is a relatively small patient population, so Vertex is working to expand into new diseases — including pain management and kidney disease — to sustain long-term growth.